Alchemy Market Research delivers an insightful market report on the global hormone replacement therapy market for making well informed strategic decisions in the market. The Global Hormone Replacement Therapy Market Size Was Estimated At USD 21.9 Billion In 2019 And Projected To Reach USD 43.05 Billion At A CAGR Of 7.8% Over The Forecast Period. This report sheds light on different parameters that help to understand the broad-ranging view of the market. It helps to make strategic decisions to various c levels business professionals such as industry leaders, investors, vendors, and various stakeholders. Furthermore, overall growth prospects are also included in the report.

Browse for full report and Free Sample Copy: https://www.alchemymarketresearch.com/healthcare/hormone-replacement-therapy-market/#req

Some significant factors such as growing demand from global consumers, Increasing hormone deficiency in both men and women, Inventions in drug discovery, increasing research and development activities by leading companies, rising needs of the global population and early aging among the global population is demanding the hormone replacement therapies widely.

Different key players in the global hormone replacement therapy market have been examined based on various factors such as company overview, financial overview, profit margin, standard operating procedures, rules, and regulations followed by global companies. With the help of SWOT and Porters five analysis techniques, leading companies have been examined and mentioned in the report.

Alchemy Market Research Profiling the Leading Key Players Functioning In the Global Hormone Replacement Therapy Market:

The global market research report has been prepared by using the following aspects of the market:

Key Questions Answered Through This Report:

Browse for full report and Free Sample Copy: https://www.alchemymarketresearch.com/healthcare/hormone-replacement-therapy-market/#req

See the original post here:
Hormone replacement therapy market- factors responsible for driving or restraining the market - Credence Turbine

Study on the Global Hormone Replacement Therapy Market

The market study on the Hormone Replacement Therapy market published by Fact.MR highlights the essential parameters that are expected to shape the growth of the Hormone Replacement Therapy market in the upcoming years. The report maps the trajectory of the Hormone Replacement Therapy market by taking into account historical data for the period between 20XX-20XX and considering 20XX-20XX as the forecast period.

The presented study evaluates the different factors that are likely to influence the dynamics of the Hormone Replacement Therapy market including the current trends and recent developments on the technological front. In addition, the micro and macro-economic factors that are likely to impact the growth of the Hormone Replacement Therapy market during the assessment period are assessed in detail.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=2224

Segmentation of the Hormone Replacement Therapy Market

The analysts have segmented the Hormone Replacement Therapy market into various sections to offer a microscopic understanding of the market. The different segments studied in the report include:

Competitive Landscape

The report on hormone replacement therapy market offers intelligence on key participants in the hormone replacement therapy market. The key companies involved in the formulation of hormone replacement therapy products are thoroughly assessed and profiled in the report. Various facets of competition including SWOT analysis, product portfolio analysis, drug developments and innovations, strategies and key financials are covered. Key companies profiled in the report include Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals, Mylan N.V and Pfizer Inc.

Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. For instance, Novartis AGs research and development department delivered 6 critical FDA breakthrough therapy designations and 16 submissions in 2017. In May 2017, Novartis AG announced U.S. FDAs approval for its hormone replacement therapy tablets for hormone receptor positive and metastatic breast cancer treatment in postmenopausal women.

In February 2018, Novo Nordisk A/S concluded main phase of REAL 1 the pivotal phase 3 trial along with somapacitan, a long-acting growth hormone to treat adults with growth hormone deficiency.

Teva Pharmaceuticals Industries Ltd. introduced Vagifem in 2017 for the treatment of atrophic vaginitis. In January 2018, the company launched Estrace cream to treat moderate and severe symptoms of vaginal and vulgar atrophy occurring due to menopause. Likewise, Mylan N.V expanded its US portfolio in the womens healthcare range with U.S. FDA approval for Estradiol Vaginal Cream to treat vaginal atrophy.

Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space. For instance, Riverside Company has acquired DoseLogix in a bid to provide innovative dosing dispensers for ensuring accurate dosing medications of hormone replacement therapy and other conditions.

Click to know more on competitive scenario in the hormone replacement therapy market to understand key strategies of market participants

Definition

Hormone replacement therapy, also referred to as menopausal hormone therapy, is used to treat various symptoms related to menopause among women. Hormone replacement therapy replaces hormones that are low in level as women near menopause. There are various types of hormone replacement therapy such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy.

About the Report

The report on hormone replacement therapy market provides incisive insights on all aspects influencing growth in demand for hormone replacement therapy worldwide. The report provides a thorough analysis on demand of hormone replacement therapy across key regions in the globe along with sales of various hormone replacement therapy products.

Key drivers, challenges, trends and opportunities shaping the growth of the hormone replacement therapy market are also covered in the hormone replacement therapy market report. The hormone replacement therapy market report provides historical data assessment on use of hormone replacement therapy, current hormone replacement therapy scenario and future demand of hormone replacement therapy. The forecast projections provided cover a timeline of 10 years (2018-2028).

Market Structure

The hormone replacement therapy market is segmented in detail to cover every angle of the hormone replacement therapy space. The hormone replacement therapy market has been segmented on the basis of product type, by dosage form, by indication, by distribution channel and by region.

Various hormone replacement therapy products such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy is covered. By dosage form, hormone replacement therapy market is segmented into tablets, patches, injections, implants and creams. By indications, hormone replacement therapy market is categorized into menopause, osteoporosis, thyroid and growth hormone deficiency. By distribution channel, it is segmented by hospital pharmacies, clinics, retail pharmacies and online pharmacies.

The hormone replacement therapy market is assessed across key regions such as North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Middle East and Africa (MEA) and Japan.

Additional Questions Answered

Apart from key findings mentioned above, the hormone replacement therapy market report also answers additional questions such as:

Research Methodology

The hormone replacement therapy market is drafted using a unique research methodology comprising of a combination of secondary and primary research methodologies. The data gleaned from primary and secondary research is assessed along with information from external sources. All the statistics are compiled using triangulation method to gain highly accurate projections on hormone replacement therapy market.

Request methodology on hormone replacement therapy market report.

Critical insights enclosed in the report:

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=2224

The report aims to provide answers to the following questions related to the Hormone Replacement Therapy market:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=2224

Why Choose Fact.MR?

Go here to see the original:
Hormone Replacement Therapy Market - Quantitative Analysis, Current and Future Trends, 2018 to 2028 - The Market Records

Over one in four female veterans say theyve used cannabis to address symptoms of menopause.

Thats even more than the percentage who report using more traditional types of menopause symptom management, such as hormone therapy, according to a study being presented today during the 2020 Virtual Annual Meeting of the North American Menopause Society (NAMS).

This study highlights a somewhat alarming trend and the need for more research relative to the potential risks and benefits of cannabis use for the management of bothersome menopause symptoms, said Dr. Stephanie S. Faubion, NAMSs medical director and a clinician who specializes in womens health.

Other experts, however, said theres good science behind the connection between menopause symptoms and the bodys natural endocannabinoid system, even if direct research on cannabiss effectiveness in addressing menopause is currently lacking.

In the new study, researchers examined data on a sample of 232 women in Northern California who took part in the Midlife Women Veterans Health Survey.

About half of the women, whose mean age was about 56 years old, reported menopause symptoms such as hot flashes and night sweats (54 percent), insomnia (27 percent), and genitourinary symptoms (69 percent).

Of these, 27 percent said they currently use cannabis (in any form) to manage their menopause symptoms or have done so in the past.

Cannabis products were most often used to address hot flashes and night sweats, researchers said.

These findings suggest that cannabis use to manage menopause symptoms may be relatively common, said Carolyn Gibson, PhD, a psychologist and health services researcher at the San Francisco Veterans Administration (VA) Health Care System and lead author of the study.

However, we do not know whether cannabis use is safe or effective for menopause symptom management or whether women are discussing these decisions with their healthcare providers particularly in the VA, where cannabis is considered an illegal substance under federal guidelines.

The study didnt differentiate between use of cannabis products containing the full spectrum of cannabis ingredients, including psychoactive tetrahydrocannabinol (THC), and those containing therapeutic doses of cannabidiol (CBD) and other cannabioids but not THC.

An additional 10 percent of the female veterans expressed an interest in trying cannabis to manage their symptoms.

By comparison, just 19 percent said they used hormone therapy or other, more mainstream interventions to manage their menopause symptoms.

This is disturbing because hormone therapy is the most effective therapy we have for menopause symptoms, and the benefits typically outweigh the risks for women in their 50s and within 10 years of menopause, Faubion told Healthline. Cannabis, on the other hand, is not a proven therapy for menopause.

Cannabis use for menopause symptoms was consistent across demographic categories, including age, race and ethnicity, socioeconomic status, and mental health conditions.

Smoking cannabis or consuming gummies or other products containing the full spectrum of cannabis ingredients, including psychoactive THC, could have mixed results for women seeking relief from menopause.

Cannabis is known to have a sedating effect, so it may have a positive effect on sleep disturbance and reduce symptoms of anxiety, but there is also evidence that cannabis use can result in lethargy, increased anxiety, and can provoke serious psychiatric illness, Samantha Miller, spokesperson for Drug Helpline, told Healthline.

Menopause is associated with cognitive changes, feelings of brain fog and difficulty concentrating. These are also side effects of cannabis use, so using cannabis might actually make these symptoms worse, she explained.

Mood changes and irritability are often prominent features during the menopause, which may be counteracted by the euphoric feelings produced by cannabis use. However, there is evidence of a higher incidence of depression in cannabis users.

Miller also pointed out that there are no reliable clinical studies looking at cannabis use to aid menopausal symptoms.

She notes that cannabis products may be illegal in some jurisdictions and are unevenly regulated.

It would be advisable to obtain these products from a reliable source and start at a low dose to assess any adverse effects, she said.

Anecdotally, however, many women have found cannabis products to be effective in treating menopause symptoms particularly insomnia and hot flashes according to Dr. Junella Chin, the chief medical advisor at CannabisMD.

Hot flashes are due to the hormonal ups and downs of menopause, Chin told Healthline. Estrogen is involved with the bodys endocannabinoid system, and CBD binds to those receptors.

She added that both CBD and THC are known for their sedative effects, which could explain their reported effectiveness against insomnia.

It makes sense that some women find relief with plant-based therapy, said Chin.

Dr. Felice Gersh, an OB-GYN and medical director of the Integrative Medical Group of Irvine, California, told Healthline that beyond hormone replacement therapy, mainstream medicine offers little in the way of relief to women suffering from menopause symptoms other than opioid or NSAID-class painkillers and anti-inflammatory drugs.

Cannabis products do offer an alternative to whats out there, she said.

Gersh recommends only organic, hemp-based products containing CBD but not THC to her menopause patients.

She cites the comparative safety of CBD and the lack of regulation of THC products, including raw cannabis.

Marijuana can be grown with a huge amount of herbicides, she noted.

Gersh added that some evidence suggests that excessive use of THC-containing cannabis can lead to cognitive problems.

On the other hand, said Gersh, The cannabinoids found in the hemp plant are very safe and have benefits for things my patients are seeking help for, including pain relief, sleep problems, and hot flashes.

Other than lacking the THC that gets users high, hemp contains all of the 80 to 100 cannabinoids and 300 noncannabinoid chemicals found in the cannabis plant.

Some of those may also play a role in addressing menopause symptoms by interacting with receptors in the brain and in the immune system, said Gersh.

I always encourage using the whole plant for the entourage effect, she said. CBD is one of the major components, but its not the only one.

The rest is here:
Why Some Experts Say Cannabis Is Effective in Treating Menopause - Healthline

T

he majority of women experience the menopause during their fifties, and one in every 100 will experience menopause before the age of 40. But who among us would think it could arrive in our thirties. Or our twenties? In truth, as the NHS website explains, premature or early menopause can occur at any age, and in many cases theres no clear cause.

This small, inconspicuous phrase has had astronomical effects on the life of Eleanor Fisher, a programme manager at Staffordshire University. Eleanor is 23 years old and has early onset menopause. After struggling with periods since the age of 18 and several years of visits to doctors and gynaecologists, Eleanor was diagnosed with pregnancy, polycystic ovaries and leukodystrophy all of which proved false.

After a third bout of no-show periods and FSH (Follicle-Stimulating Hormone the hormone that instigates the growth of ovarian follicles before the release of an egg) levels off the scale, Eleanor was finally told that she had the menopause. Shes now two months into Hormone Replacement Therapy (HRT) treatment.

Visit link:
Medical profession cares little for women with early onset menopause - The Independent

The Global Hormone Replacement Therapy (HRT) Tablets market report offers all the company profiles of the leading players and brands. The drivers and restrictions of the market have been explained with the help of the SWOT analysis and the Porter Five Forces tool. Hormone Replacement Therapy (HRT) Tablets market report is an in-depth study of the healthcare industry that explains the definition of the market, classifications, applications, commitments and global industry trends. This report gives the opportunity not only to compete but to surpass the competition.

The Hormone Replacement Therapy (HRT) Tablets market is divided into products, applications, end users and regions. The analysis of the historical year and the base year 2017 in 2016 shows that new highs will be achieved in the 2019-2026 Hormone Replacement Therapy (HRT) Tablets market. The best players and brands on the market make calculated movements such as product launches, research, joint ventures, mergers and acquisitions.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hormone-replacement-therapy-hrt-tablets-market

Hormone replacement therapy (HRT) tablets marketis expected to rise with a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increased development of drugs with better therapeutic profiles. The report contains data of the base year 2018 and historic year 2017.

Few of the major competitors currently working in the global hormone replacement therapy (HRT) tablets market areALLERGAN, Novo Nordisk A/S, Sanofi, Abbott, TherapeuticsMD, Inc., Mithra Pharmaceuticals among others.

Key Development in the Market:

Market Drivers:

Market Restraints:

Speak To Industry Experts, Request For Details Report At: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hormone-replacement-therapy-hrt-tablets-market

Segmentation: Global Hormone Replacement Therapy (HRT) Tablets Market

By Type of Disease

By Treatment Type

By End-User

By Distribution Channel

By Geography

To know more about the study @https://www.databridgemarketresearch.com/reports/global-hormone-replacement-therapy-hrt-tablets-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

Excerpt from:
Global Hormone Replacement Therapy (HRT) Tablets Market Covid 19 Overview:Demand Analysis & Growth Opportunities By 2019-2026||ALLERGAN, Novo...

Transgender youth tend to suffer from higher rates of anxiety, depression, self-harm, and thoughts of suicide than their peers. But a new study published in Pediatrics found that early gender-affirming care may have a direct, positive impact on mental health.

The study, which surveyed 300 transgender children aged between 10 and 17 years old at the Hospital for Sick Children in Toronto, Canada, found transgender youth who received transitionary care such as hormone blockers and hormone replacement therapy at earlier ages reported lower rates of depression, self-harm, and suicidal thoughts.

Researchers say this is likely because younger trans youth, defined by the study as being under 15 years old, have yet to go through puberty-induced bodily changes that can cause gender dysphoria, or the distress that occurs when one's body does not reflect the gender identity they are.

Getting gender-affirming care before puberty can slow or stop some of the changes that are more difficult to reverse like voice deepening, hair growth, and fat distribution.

"Our data add to the existing literature, suggesting that distress may be particularly profound among [trans youth] who present for care at older ages and with more advanced puberty," researchers wrote.

The researchers found that, among children under 15 who received gender-affirming medical care, 3o% reported depression, compared to 45% of those who received care later. They were also less likely to report suicidal ideations (40% compared to 52%), and less likely to have engaged in self-harm (28% compared to 40%).

Younger children who received care between the ages of 10 to 15, rather than over 15, were also far less likely to attempt suicide (9% did, compared to 17% of those who received care later).

The data underscore existing best medical practices that state transgender youth should receive transitionary care regardless of their age, as gender-affirming care can be the difference between life and death.

Donald Iain Smith/Getty Images

This study is not the first to link gender affirmation, whether it be medical or social, to better mental health outcomes for trans youth.

A PNAS study published in November 2019 found transgender children who were able to live as the gender they were rather than the gender they were assigned developed their gender identity, likes, and interests at the same time their cisgender peers did.

Another study published in Pediatrics in March 2016 found transgender children who were able to socially transition or live as the gender they are rather than the one they were assigned through pronouns, name, and gender presentation had lower rates of anxiety and depression later in life.

Children who were able to use their chosen name rather than the name they were assigned at birth as part of their transition had lower rates of suicidal ideations and attempted suicide than children who were not supported in their transition, according to a study published in the Journal of Adolescent Health in 2018.

The findings are especially significant in light of local state legislatures like South Dakota, Idaho, and Florida attempting to pass age restrictions that would make it illegal for doctors to provide gender-affirming care like HRT and hormone blockers to anyone under 18.

"Gender-affirming health care saves lives," Shawn Meerkamper and Dale Melchert, senior staff attorney and staff attorney for the Transgender Law Center who were not involved in the study, previously told Insider.

Read More:

South Dakota doctors who offer transgender kids hormone treatments and puberty blockers could face jail time if lawmakers pass a new bill

A Georgia lawmaker wants to make treatments for transgender kids a felony, but doctors say that could put lives at risk

Transgender kids aren't just 'going through a phase' and develop like their non-trans peers, researchers say

See original here:
Trans youth are less likely to have suicidal thoughts with early care - Insider - INSIDER

I wasnt pregnant, overweight or too thin. I wasnt exercising too much or eating too little. From all appearances, I was a normal, healthy woman, but by the time I was in my mid-20s, I hadnt menstruated in four years.

My periods had never been regular, but I was accustomed to getting one at least three to four times a year. My doctors told me that I was a normal, healthy woman, at least in reproductive terms. But I was desperate to discover where my absent monthly visitor had gone, and why. My blood tests showed that my female sex hormonesestradiol and progesteronewere near menopausal levels, which put me at a risk for osteoporosis. I knew menopause could come early, but I was just 24.

To get answers, I turned to the internet late one Saturday night. Menopause, it told me, is the time when there have been no menstrual periods for 12 consecutive months, with no other biological or physiological cause identified. Using that definition as a guide, I was already in my fourth year of menopause, at least two decades early.

Most of my friends were well into their womanhood, seemingly in control of their regular periods and at the peak of their fertility. And then there was me. I wasnt a part of the menstruation camaraderie shared between many women. Instead, I identified more with women my mothers age.

Much of my early twenties was spent visiting doctors offices in search of answers. One doctor feared I had a tumor in my pituitary gland, a pea-sized organ in the brain that regulates vital body functions and general wellbeing. I was injected with a gadolinium-based contrast agent and had an MRI of my brain that, thankfully, came out negative. Another doctor misdiagnosed me with an underactive thyroid and prescribed thyroid medication. Even if that had been the problem, she also overmedicated me, throwing me into a fit of uncontrollable anxiety with equal parts impending doom, rapid heartbeat and shortness of breath. I lived in that state for several manic weeks.

My friends were well into their womanhood, seemingly in control of their regular periods. And then there was me. ... I identified more with women my mothers age.

It was hard to trust specialists after that experience, so I returned to my 62-year-old gynecologist, who had also been my mothers. (Technically, we had first met when he pulled me out of her.) I felt he was someone who would tell me the truth. Honey, relax, he told me. Theres no medical reason why you need to have a period. Most women would love to have your problem! While I pushed back against his supposed wisdom, he prepped me for an ultrasound.

Next thing I knew, I was lying on my back with my feet pressed against elevated, chilly metal stirrups. This will feel cold, an ultrasound technician said as she moved the wand around inside of me. Clenching my jaw and bunching the medical exam tissue paper beneath me, I did my best to relax. The technician, meanwhile, casually displayed my ovaries on a screen next to us.

I hoped the images of my insides would reveal the mystery of my missing periods. The technician used a digital ruler to measure many black ovals, some over an inch in size. She described them as a string of pearls. Confused, all I could do was make a joke: I didnt imagine my first set of pearls to look like this!

My doctor later looked at the images and my lab work and diagnosed me with Polycystic Ovarian Syndrome. Unlike most people who face a diagnosis with an odd acronym, PCOS was actually on my radar. My mother had suffered from it for decades. So why did it take years to figure out that I had the same thing? In part, it is because our symptoms are entirely different. For her, PCOS explained her extremely heavy periods that left her in crippling pain. But that had never been my problem.

I had so many questions for my doctors: How can my mom and I have the same diagnosis, but diametrically opposing experiences with menstruation? Is there any treatment? Is this the reason Ive been feeling so depressed and anxious? Will I be able to have kids one day?

While I finally had a diagnosis, it was oddly vague. It all left me wondering what, exactly, do I suffer from?

Instead of answering them, my doctor picked up his pen, scribbled some notes and sent me on my way with a prescription for anti-depressants and oral contraceptives. I had no history of clinical depression and in retrospect, the anxiety was probably from the sudden chaos inside me that the diagnoses triggered. As for the birth control pills, he said it was the only treatment for the newly diagnosed syndrome Id been living with for years.

Unsatisfied with his answers (or lack thereof), I emailed my general practitioner to express my concerns. While I was used to him speaking in terse, broken sentences, I expected a bit more guidance. If not sexually active, don't worry about periods for now, he wrote. Enjoy life and use condoms if needed. You should be doing that anyway. Not uncommon for periods to disappear from time to time. Don't lose any sleep over it.

But, of course, I lost a whole lot of it as I spent hours digging to the depths of the internet to research my condition each night. I discovered that there is no single test to definitively diagnose PCOS and there is no universally accepted definition. In fact, the diagnostic criteria have actually expanded in recent years, according to the American College of Obstetricians and Gynecologists. So, while I finally had a diagnosis, it was oddly vague. And because my symptoms were not as extreme as some of my fellow cysters, I felt a sense of shame amid my struggle. It all left me wondering what, exactly, do I suffer from?

Much to my dismay, this wasnt something Google could answer. Though I did learn that PCOS is one of the most common causes of female infertility, affecting five to 10 percent of women of childbearing age in the United States. Despite the syndromes prevalence, it is regarded as one of the most neglected public health issues. Women with PCOS are more prone to diabetes, sleep apnea, and heart disease, and three times more likely to get endometrial cancer.

Given the stakes, I couldnt believe physicians werent more attuned to the symptoms. I wasnt alone in that sentiment. Surveys show that women with the syndrome have a very high degree of dissatisfaction with their diagnostic experience. In a survey of 1,385 PCOS sufferers from 48 different countrieshalf from the United Statesresearchers at Monash University found that one in three women had suffered for more than two years before receiving a diagnosis. They also went to three or more medical providers with different specialties in the process.

Anti-depressants, metformin, spironolactone, herbal supplements, birth controlyou name it, I tried it. Despite having the correct diagnosis, I never received the right care. That was until my first gynecologist referred me to a reproductive endocrinologist, Sharon Winer.

Anti-depressants, metformin, spironolactone, herbal supplements, birth controlyou name it, I tried it. Despite having the correct diagnosis, I never received the right care.

Dr. Winer spent two hours looking over all my tests and writing down details of my saga. Most importantly, she helped me digest and understand medical terms in a way no other doctor had ever attempted. I learned that my body produced too much testosteronethe male sex hormoneand insulin, the hormone that manages our blood sugar levels. This, in conjunction with my low levels of estrogen, were likely the reason behind my missing period, weight gain and fatigue. I learned that insulin resistance is very much associated with PCOS, even though its not currently one of the diagnostic criteria.

Winer explained that birth control was not the right treatment for me because it was further suppressing my hormones by continuing to switch them off. After careful consideration, she prescribed me Hormone Replacement Therapy, known as HRT, to be taken cyclically to mimic a real menstrual cycle. This is a common menopause treatment, but in my case, the doctor hoped it would wake my endocrine system up and cause it to produce these hormones.

Two months later, I got my first period in four and a half years. It wasnt much, but in a way, it was everything. It proved to me that my body wasnt broken. I weaned off the hormones six months later, only to see my body working as it should. It was capable all along. It just needed the right guidance. I called my mom and we both cried.

After six years, three misdiagnoses, and countless ups and downs, I have finally found a way to manage my symptoms through medication, diet, and exerciseall without surrendering to a one-pill fix. Some people keep track of the miles they run every week, others count calories; for me, the anchor that defines whether Im in good health stems from the monthly rhythm of my menses.

Two years and three months later, I can safely say that tapping the add cycle button on my period tracker phone app never gets old.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read more here:
Solving the Mystery of My Missing Menstruation - ELLE.com

Global Hormone Replacement TherapyMarket report forecast 2020-2025 investigate the market size, manufactures, types, applications and key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hormone Replacement Therapy market in these regions. This report also covers the global Hormone Replacement Therapy market share, competition landscape, status share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Global Hormone Replacement Therapy Market are mentioned in the competition landscape, company overview, financials, recent developments and long-term investments. Various parameters have been studied while estimating the market size. The revenue generated by the leading industry participants in the sales of the Hormone Replacement Therapy markethas been calculated through primary and secondary research.

Get PDF Sample Copy of the Report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/180993

Top Key players profiled in the Hormone Replacement Therapy market report include:F. Hoffmann-La Roche, Merck Serono, Novartis, Novo Nordisk, Pfizer, Abbott Laboratories, ANI Pharmaceuticals, Bayer, Eli Lilly, Hisamitsu Pharmaceutical, Merck, Mylan Laboratories and More

Market Segment By Type:Estrogen replacement therapyGrowth hormone replacement therapyMarket Segment By Application:OralParenteralTransdermal

global Hormone Replacement Therapy market report also highlights key insights on the factors that drive the growth of the market as well as key challenges that are required to Hormone Replacement Therapy market growth in the projection period. Here provide the perspectives for the impact of COVID-19 from the long and short term. Hormone Replacement Therapy market contain the influence of the crisis on the industry chain, especially for marketing channels. Update the industry economic revitalization plan of the country-wise government.

To Understand the influence of COVID-19 on the Set Screw Market with our analysts monitoring the situation across the globe. Get here sample analysis

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/180993

Key point summary of the Global Hormone Replacement Therapy Market report:

Detailed TOC of Hormone Replacement Therapy Market Report 2020-2025:

1 COVID-19 Impact on Hormone Replacement Therapy Market Overview

1.1 Product Definition and Market Characteristics

1.2 Global Hormone Replacement Therapy Market Size

1.3 Hormone Replacement Therapy market Segmentation

1.4 Global Macroeconomic Analysis

1.5 SWOT Analysis

2 COVID-19 Impact on Hormone Replacement Therapy Market Dynamics

2.1 Hormone Replacement Therapy Market Drivers

2.2 Hormone Replacement Therapy Market Constraints and Challenges

2.3 Emerging Market Trends

2.4 Impact of COVID-19

2.4.1 Short-term Impact

2.4.2 Long-term Impact

3 Associated Industry Assessment

3.1 Supply Chain Analysis

3.2 Industry Active Participants

3.2.1 Suppliers of Raw Materials

3.2.2 Key Distributors/Retailers

3.3 Alternative Analysis

3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Hormone Replacement Therapy Market Competitive Landscape

4.1 Industry Leading Players

4.2 Industry News

4.2.1 Key Product Launch News

4.2.2 M&A and Expansion Plans

5 Analysis of Leading Companies

5.1 Company A

5.1. Company Profile

5.1.2 Business Overview

5.1.3 Hormone Replacement Therapy market Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)

5.1.4 Hormone Replacement Therapy market Products Introduction

5.2 Company B

5.2.1 Company Profile

5.2.2 Business Overview

5.2.3 Hormone Replacement Therapy market Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)

5.2.4 Hormone Replacement Therapy market Products Introduction

6 Hormone Replacement Therapy Market Analysis and Forecast, By Product Types

6.1 Global Hormone Replacement Therapy Market Sales, Revenue and Market Share by Types (2015-2020)

6.2 Global Hormone Replacement Therapy Market Forecast by Types (2020-2025)

6.3 Global Hormone Replacement Therapy Market Sales, Price and Growth Rate by Types (2015-2020)

6.4 Global Hormone Replacement Therapy Market Revenue and Sales Forecast, by Types (2020-2025)

7 Hormone Replacement Therapy Market Analysis and Forecast, By Applications

7.1 Global Hormone Replacement Therapy Market Sales, Revenue and Market Share by Applications (2015-2020)

7.2 Global Hormone Replacement Therapy Market Forecast by Applications (2020-2025)

7.3 Global Hormone Replacement Therapy Market Revenue, Sales and Growth Rate by Applications (2015-2020)

7.4 Global Hormone Replacement Therapy Market Revenue and Sales Forecast, by Applications (2020-2025)

Continued

For More Information with full TOC: https://www.marketinforeports.com/Market-Reports/180993/Hormone-Replacement-Therapy-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/180993/Hormone-Replacement-Therapy-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: s[emailprotected]Website: http://www.marketinforeports.com

Follow this link:
Hormone Replacement Therapy Market share forecast to witness considerable growth from 2020 to 2025 | By Top Leading Vendors F. Hoffmann-La Roche,...

Pune, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The global genomics market size is projected to reach USD 82.60 billion by the end of 2027. The massive investments in the research and development of efficient products will have a massive impact on the growth of the market in the coming years.

According to a report published by Fortune Business Insights, titled Genomics Market Size, Share & COVID-19 Impact Analysis, By Type (Products (Instruments & Software and Consumables) and Services), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Microarray, Sanger Sequencing, and Others), By Application (Diagnostics, Research, and Others), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)), and Regional Forecast, 2020-2027, the market was worth USD 18.85 billion in 2019 and will exhibit a CAGR of 19.5% during the forecast period 2020-2027.

Genomics is a concept that involves the human gene and sequencing for treatment and study of several diseases or potential diseases. The study of human genetics helps identify and track critical diseases, with equal focus on the qualities and behaviour of a specific individual. In the past few years, genomics has contributed to the growth of numerous similar branches including the popular precision medicine.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941

The massive investments in the research and development of genomics and genomic sequencing will have a positive impact on the growth of the overall market in the coming years. The presence of several large scale companies has had a massive impact on the growth of the market in recent years and the influx of start-ups will create opportunities for growth in the foreseeable future.

Recent Clinical Studies have Indicated the Potential of Genomics to Tracking Patterns of Covid-19 Spread

The recent coronavirus outbreak has created a sense of panic among businesses across the world. Although healthcare industry has witnessed a contrasting impact, as compared to a few other sectors, there has been a recent surge in the need for healthcare professionals. The lack of skilled labour is consequential to the hesitancy among workers due to the severity of the disease. Although there are several ongoing research activities associated with the treatment of the coronavirus, there has been little success in this field.

Accounting to increasing cases of Covid-19 across the world, researchers are focusing on implementing preventive and precautionary measures through newer concepts. The excessive research associated with the use of genomics in Covid-19 pandemic has yielded a few successful measures. As a result, genomics has recently attracted attention from across the world.

The whole world is fighting the novel coronavirus. Sectors and industries are devasted due to the major loss caused by COVID-19 in business. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.

To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941

Constant Product Innovations are Consequential to Increasing R&D Efforts

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Among all factors, the increasing number of product innovations, driven by rising investments in the research and development of the product, has made the highest impact on the growth of the market. In April 2020, Eurofins announced the launch of a new product in the genome sequencing space.

The company introduced SARS-CoV 2 full length genome sequencing, a product that is categorized under the next-generation (NGS) sequencing category. Increasing number of such product innovations will have a positive impact on the growth of the overall market in the coming years.

North America to Emerge Dominant; Increasing Activities associated with Whole-genome Sequencing will Emerge in Favor of Market Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing research activities associated with whole-genome sequencing by private companies as well as government organizations will contribute to the growth of the regional market.

As of 2019, the market in North America was worth USD 8.27 billion and this value is projected to rise at a considerable pace in the coming years. The market in Asia Pacific will derive growth form the efforts put in towards genetic sequencing by countries such as China.

Quick Buy - Genomics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100941

List of companies profiled in the Genomics Market report:

Industry Developments:

February 2020: Nebula Genomic announced the launch of a new product that will offer whole genome sequencing at US$ 299 to its customers.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/genomics-market-100941

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/genomics-market-100941

Have a Look at Related Reports:

Next-Generation Sequencing (NGS) Market Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026

Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Polymerase Chain Reaction (PCR) Market Share & Industry Analysis, By Type (Standard PCR, Real-time PCR, and Digital PCR), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026

Hormone Replacement Therapy (HRT) Market Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies), and Regional Forecast, 2019-2026

Heart Valves Market Share & Industry Analysis, By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/genomics-market-9172

See the original post here:
Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,...

Contrary to prior understanding, many hormones related to spermatogenesis take longer to recover than previously thought, and up to 3 years in some cases after anabolic steroid misuse, according to a fertility expert speaking at the Royal Society of Medicine webinar series.

Dr Channa Jayasena, consultant in reproductive endocrinology and andrology at Imperial College and Hammersmith Hospital, London, gave a talk on male hypogonadism that he admitted might seem provocative to some people but addresses issues that extend current knowledge. The three key issues discussed were: how quickly can men recover fertility after androgen use; how to assist azoospermic men with Klinefelter syndrome (or XXY) father children; and whether testosterone therapy affects progression to diabetes in obese men.

Dr Jayasena spoke at last weeks 3-day webinar held by the Royal Society of Medicine, Endocrinology and Diabetes section, entitled, EDN50:What's new in endocrinology and diabetes 2020?

He began by asking how quicky do men who take anabolic steroids recover fertility? "This has never been studied to much extent."

Self-confessed steroid user and reality television star, Spencer Matthews, said in a tabloid newspaper article that the UK is in the grips of an epidemic of anabolic steroid use, Dr Jayasena remarked. "I see men who take anabolic steroids but then they want a baby and want to know whats next?"

The nearest data to understanding recovery from anabolic steroids comes from studies of the male pill, said the andrologist. This involves giving a high level of progesterone to suppress luteinising hormone and follicle stimulating hormone (in effect the male pill), and then giving the men testosterone replacement. A Lancet paper (Liu at al 2006) involving this regimen looked at the time from stopping the male pill to recovery of sperm. It shows that, by 12 months, all participants had recovered some sperm function, with 80% recovering to the pre-treatment semen level, explained Dr Jayasena. "This has long been presumed to be the measure of recovery. However, this does not resonate with reality and the observation that actually there are many people who dont recover within this time frame and take a lot longer, some with azoospermia[semen containing no sperm]," he pointed out.

Another cross-sectional observational study looked at 41 current users of anabolic steroids, 31 recent ( 3 months since last use), and 21 healthy eugonadal men. All were 18-55 years, exercising at least three times a week. "The critical strength of this study is that these men were all clinically indistinct," Dr Jayasena remarked. "This matching of baseline characteristics is critical for interpretation of the data. Due to recruitment issues, weve never had such a good look at recovery in this way before."

The study looked at the reproductive endocrine profiles including the levels of luteinising hormone, follicle stimulating hormone, and testosterone. In current users, the former two were suppressed and the testosterone level was high, as expected, displaying a hypogonadatropic profile. "Past users and non-users have very similar profiles, suggesting reversible luteinising hormone and follicle stimulating hormone suppression," said Dr Jayasena, adding, "this is really interesting and looking at acne, gynaecomastia, hair loss and smaller testicles all classical features of androgen abuse - appear to persist in many of the men who are past users. Its important we counsel these men that we, the clinicians, are not really clear about how long these side effects will persist."

Results also showed low HDL cholesterol and high triglycerides in users, but not in non-users or past users, and cardiac hypertrophy in users but not past users. "The latter finding is encouraging," Dr Jayasena pointed out.

Regarding fertility, the study by Shankara-Naranya found that when comparing non-users to users of anabolic steroids, it took a mean of 10.7 months for users to recover their luteinising hormone levels to the mean luteinising hormone of a non-user. "But recovery time is highly variable. Luteinising hormone (and testosterone by inference), and sperm concentration seem to recover within a year, with a mean of 10 months, but all the other hormones that are important for spermatogenesis take much longer to recover so follicle stimulating hormone was 20 months, inhibin B was 32 months, sperm motility was 38 months, up to 3 years to recover. This is critical and we didnt know this," reported Dr Jaysena.

"In answer to what is the prognosis for recovery in men after androgen misuse? The endocrine system mostly recovers in the first year but sperm take much longer to recover," he concluded.

Along with Downs syndrome, Klinefelter is the most common chromosomal disorder in men, affecting 1 in 500 men. A total of 90% of those with Klinefelter syndrome are azoospermic, and it has long been assumed to be incompatible with fatherhood.

"Things have changed, and Id like to ask what is the chance of fatherhood for a man with XXY undergoing microdissection testicular sperm extraction (mTESE)?" said Dr Jayasena. "This can be done by dissecting open a testicle and looking for an engorged seminiferous tubule that is likely to be full of sperm," he explained. "If this is confirmed, after some processing, the sperm can be used in intracytoplasmicsperm injection (ICSI)."

It has been known that it was possible for patients with Klinefelter syndrome to father children for the past 20 years, but, asked Dr Jayasena, how successful is it? "Its still an embryonic field," he noted. Referring to a meta-analysis of 37 studies, Dr Jayasena said 40% of men with Klinefelters syndrome had sperm retrieved, and of these 40%, an average of nearly 50% of men had live births after ICSI. But some studies reported 10% and others 90%.

In conclusion, the chances of fatherhood in XXY men undergoing mTESE, is around 20% but a large randomised controlled trial (RCT) is needed to confirm this, said Dr Jayasena.

Finally, the researcher moved on to the third topic of whether testosterone therapy improves the effectiveness of weight loss in men over 50 years with type 2 diabetes. Referring to outcomes of the largest, as yet unpublished, testosterone trial ever, in more than 1000 men by Dr Gary Wittert, from the University of Adelaide, Dr Jayasena described the study.

Most importantly, they did not select men with hypogonadism these results are not valid for hypogonadism because not all men had hypogonadism, explained Dr Jayasena. Two-hour plasma glucose was 7.8 to 15 mmol/l. The men were randomised to Weight Watchers weight loss programme plus placebo versus the same weight loss programme plus testosterone. They also excluded men with high cardiovascular risk, due to a Food and Drug Administration [FDA] unproven concern about cardiovascular risk. "Testosterone may be dangerous in some of these men (59-75 years and obese) in real life," he pointed out.

The paper is currently in review but some preliminary findings were presented at a conference earlier this year. Dr Jayasena says: "If testosterone improves the prevention of type 2 diabetes during weight loss in men without hypogonadism, then that would challenge our understanding of how it works. However, testosterone is still not a treatment to prevent type 2 diabetes,"

To answer the question definitively, said Dr Jayasena, confirmatory data, mechanistic data, and safety data are needed.

COI: Dr Jayasena received an honorarium for speaking during a debate organised by the Society for Endocrinology and sponsored by Besins Healthcare. He has an investigator-led grant by Logixx Pharma Ltd.

Presented at the Royal Society of Medicine, Endocrinology and Diabetes section, entitled, EDN50: What's new in endocrinology and diabetes 2020? , Day 3. September 23, 2020

Continue reading here:
Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape